
Recent Congressional Hearings Expose Weak and Vague Arguments From PBM Executives We may finally have an answer (for now) to the question of who is really responsible for the increases in drug costs and the corresponding increase in negative patient outcomes. A new bill was introduced following the House Oversight and Accountability Committee hearing, where,… Read more »